News: IVD

Here are your up-to-date news results!
Clicking the title of the article will give you the original publication.
You can share an article quickly with colleagues via Twitter and LinkedIn!


Gatehouse Bio collaborates with AstraZeneca to accelerate new drug discovery
Published:

Gatehouse Bio’s ‘sRNAlytics platform’ identifies novel small RNA (sRNA) signatures and illuminates molecular pathways correlated to and potentially driving disease. “Our annotation library of over 1.4M small RNA

The post Gatehouse Bio collaborates with AstraZeneca to accelerate new drug discovery appeared first on Pharmaceutical Business review.

AWS announces strategic collaboration with Novartis to accelerate digital transformation of its business operations
Published:

This enterprise-wide data and analytics platform is expected to form the foundation for custom solutions powered by AWS AI and ML services to help drive agility, innovation, and

The post AWS announces strategic collaboration with Novartis to accelerate digital transformation of its business operations appeared first on Pharmaceutical Business review.

Bristol-Myers Squibb gets FDA breakthrough therapy status for Orencia to prevent GvHD
Published:

GvHD is a potentially life-threatening medical complication, which can affect patients receiving such transplants to treat certain genetic diseases and haematologic cancers. Orencia is an immunomodulator that disturbs

The post Bristol-Myers Squibb gets FDA breakthrough therapy status for Orencia to prevent GvHD appeared first on Pharmaceutical Business review.

Irish growth opportunities highlighted at Medtech Rising
Published: 5 Dec 2019 | 14:34 UTC

The Irish Medtech Association, the Ibec group that represents the medtech sector, Enterprise Ireland and IDA Ireland has highlighted global growth opportunities for the Irish medtech industry at Medtech Rising: The Irish Medtech CEO Conference.

Medical device industry sees 12.7% rise in deal activity - GlobalData
Published: 5 Dec 2019 | 10:07 UTC

Europe’s medical devices industry saw a rise of 12.7% in overall deal activity during Q3 2019, when compared to the four-quarter average, according to GlobalData’s deals database.

Collaboration established to deliver federated learning in life sciences
Published: 5 Dec 2019 | 9:34 UTC

Owkin, which is developing federated learning and AI technologies to advance medical research, has announced a collaboration with technology firm NVIDIA and King’s College London (KCL) to deliver federated learning in healthcare and life sciences.

Rare disease diagnostics firm Centogene completes $52mm IPO on Nasdaq
Published: 26 Nov 2019 | 5:40 UTC

German biotech Centogene BV (rare disease diagnostics and biomarker discovery) netted $52mm in its initial public offering on Nasdaq of 4mm shares at $14, the low end of its anticipated $14-16 range.

Rare disease diagnostics firm Centogene completes $52mm IPO on Nasdaq
Published: 26 Nov 2019 | 5:40 UTC

German biotech Centogene BV (rare disease diagnostics and biomarker discovery) netted $52mm in its initial public offering on Nasdaq of 4mm shares at $14, the low end of its anticipated $14-16 range.

Exagen completes $53.9mm IPO, five years after first filing
Published: 19 Nov 2019 | 17:29 UTC

Exagen Diagnostics Inc. (autoimmune disease testing and therapeutic drug monitoring) netted $53.9mm through its initial public offering of 4.14mm common shares (including the overallotment) at $14. The company first filed for an IPO back in 2014, but never completed the process.

Exagen completes $53.9mm IPO, five years after first filing
Published: 19 Nov 2019 | 17:29 UTC

Exagen Diagnostics Inc. (autoimmune disease testing and therapeutic drug monitoring) netted $53.9mm through its initial public offering of 4.14mm common shares (including the overallotment) at $14. The company first filed for an IPO back in 2014, but never completed the process.

Sera Prognostics closes $36mm Series D round
Published: 15 Nov 2019 | 5:40 UTC

Sera Prognostics Inc. (proteomics tests for the early prediction of preterm birth defects and other pregnancy-related complications) closed a $36mm Series D round co-led by new investor Blue Ox Healthcare and two undisclosed healthcare companies. Returning backers Domain Associates, InterWest Partners, Laboratory Corp. of America Holdings, Catalyst Health Ventures, and Chione Ltd. also participated. The company will use the proceeds to expand commercialization of and improve its clinically validated PreTRM, a biomarker blood test that assesses individualized risk of premature delivery. Since its 2008 inception, Sera has raised $122mm.

Sera Prognostics closes $36mm Series D round
Published: 15 Nov 2019 | 5:40 UTC

Sera Prognostics Inc. (proteomics tests for the early prediction of preterm birth defects and other pregnancy-related complications) closed a $36mm Series D round co-led by new investor Blue Ox Healthcare and two undisclosed healthcare companies. Returning backers Domain Associates, InterWest Partners, Laboratory Corp. of America Holdings, Catalyst Health Ventures, and Chione Ltd. also participated. The company will use the proceeds to expand commercialization of and improve its clinically validated PreTRM, a biomarker blood test that assesses individualized risk of premature delivery. Since its 2008 inception, Sera has raised $122mm.

Opko, BMS aim to develop Alzheimer’s blood test
Published: 23 Oct 2019 | 3:40 UTC

Opko Health Inc. (point-of-care and molecular diagnostics and vaccines) and Bristol-Myers Squibb Co. will nonexclusively collaborate on the further development of Opko’s Alzheimer’s disease blood test.

CellaVision pays SEK268mm for RAL Diagnostics
Published: 12 Oct 2019 | 3:40 UTC

CellaVision AB acquired privately held cellular imaging company RAL Diagnostics for SEK268mm ($29.8mm).

Takeda and Prometheus Biosciences enter IBD partnership
Published: 9 Oct 2019 | 3:40 UTC

Takeda Pharmaceutical Co. Ltd. penned an agreement with Prometheus Biosciences Inc. (formerly Precision IBD) for the discovery and development of up to three new therapies (and related companion diagnostics) for inflammatory bowel disease (IBD).

NeuCyte licenses Trillium's epilepsy candidate
Published: 28 Sep 2019 | 3:40 UTC

NeuCyte Inc. licensed exclusive worldwide development and commercialization rights to Trillium Therapeutics Inc.'s undisclosed refractory epilepsy compound for Dravet syndrome and related disorders.

Curetis, OpGen merge
Published: 6 Sep 2019 | 3:40 UTC

Curetis NV and fellow public infectious disease-focused molecular diagnostics firm OpGen Inc. are reverse merging.

Exact Sciences and Genomic Health merge in $2.8bn deal
Published: 31 Jul 2019 | 3:41 UTC

Exact Sciences Corp. and Genomic Health Inc. have agreed to merge in a $2.8bn deal that would create a leading global molecular diagnostics company.



Please note that GR Consulting can not alter or influence the messages displayed, nor is it responsible for its content. If needed or desired, please refer to the original message and/or its originator.